Inventor · disambiguated record
Aris N. Economides
Also filed as: ECONOMIDES ARIS · ECONOMIDES ARIS N
53 granted patents·19 pending applications·1,088 citations·filing 1993–2024
98Inventor score
Files withREGENERON PHARMA61ECONOMIDES ARIS N3MURPHY ANDREW J2CORNELL RES FOUNDATION INC1MARTIN JOEL H1
Top patents by PatentIndex Score
72 records- 0199US7205148B2Genome mutation by intron insertion into an embryonic stem cell genomeREGENERON PHARMA·Filed 2004·Granted Apr 17, 2007·93 cites·9 claims
- 0299US6586251B2Methods of modifying eukaryotic cellsREGENERON PHARMA·Filed 2000·Granted Jul 1, 2003·505 cites·14 claims
- 0398US8791323B2Hybrid antibodies comprising human variable regions and mouse constant regions produced in a genetically modified mouseMURPHY ANDREW J·Filed 2006·Granted Jul 29, 2014·97 cites·3 claims
- 0497US8759105B2Method for genetically modifying mouse embryonic stem cell by homologous recombinationECONOMIDES ARIS N·Filed 2007·Granted Jun 24, 2014·40 cites·10 claims
- 0596US8846402B2Method for genetically modifying isolated non-human mammalian cell by homologous recombinationREGENERON PHARMA·Filed 2012·Granted Sep 30, 2014·17 cites·54 claims
- 0695US9708635B2Methods of making a nucleic acid encoding a human variable regionREGENERON PHARMA·Filed 2012·Granted Jul 18, 2017·9 cites·10 claims
- 0794US11578135B2Multispecific antigen-binding molecules binding to a target and an internalizing effector protein that is CD63 and uses thereofREGENERON PHARMA·Filed 2019·Granted Feb 14, 2023·8 cites·14 claims
- 0894US10640800B2Mice that produce hybrid antibodiesREGENERON PHARMA·Filed 2016·Granted May 5, 2020·4 cites·6 claims
- 0994US9999207B2Nucleic acid construct for making a genetically modified rodent with an inducible ACVR1 mutation that causes ectopic bone formationREGENERON PHARMA·Filed 2016·Granted Jun 19, 2018·6 cites·3 claims
- 1094US9510569B2Genetically modified mouse with an inducible Acvr1 gene with a mutant R206H exon 5 that has ectopic bone formationREGENERON PHARMA·Filed 2014·Granted Dec 6, 2016·12 cites·4 claims
- 1194US9388446B2Methods of producing hybrid antibodiesREGENERON PHARMA·Filed 2013·Granted Jul 12, 2016·6 cites·8 claims
- 1293US9353394B2Methods of producing hybrid antibodiesREGENERON PHARMA·Filed 2013·Granted May 31, 2016·6 cites·7 claims
- 1392US9528136B2Methods of modifying eukaryotic cellsREGENERON PHARMA·Filed 2013·Granted Dec 27, 2016·5 cites·9 claims
- 1492US9371553B2Genetically modified mice that produce hybrid antibodiesREGENERON PHARMA·Filed 2013·Granted Jun 21, 2016·6 cites·5 claims
- 1591US10378040B2Mice that produce hybrid antibodiesREGENERON PHARMA·Filed 2013·Granted Aug 13, 2019·4 cites·4 claims
- 1691US10344299B2Compositions and methods for modifying cellsREGENERON PHARMA·Filed 2017·Granted Jul 9, 2019·3 cites·13 claims
- 1791US5844099ACytokine antagonistsREGENERON PHARMA·Filed 1995·Granted Dec 1, 1998·87 cites·17 claims
- 1890US9376699B2Methods of producing hybrid antibodiesMURPHY ANDREW J·Filed 2011·Granted Jun 28, 2016·4 cites·8 claims
- 1989US10526630B2Genetically modified mice that produce hybrid antibodiesREGENERON PHARMA·Filed 2013·Granted Jan 7, 2020·3 cites·2 claims
- 2089US10378037B2Methods of making a nucleic acid encoding a human variable regionREGENERON PHARMA·Filed 2013·Granted Aug 13, 2019·3 cites·10 claims
- 2189US10378039B2Mouse embryonic stem cells comprising a hybrid heavy chain immunoglobulin locusREGENERON PHARMA·Filed 2013·Granted Aug 13, 2019·3 cites·4 claims
- 2289US10378038B2Mice that produce hybrid antibodiesREGENERON PHARMA·Filed 2013·Granted Aug 13, 2019·3 cites·3 claims
- 2389US10227625B2Methods of modifying eukaryotic cellsREGENERON PHARMA·Filed 2012·Granted Mar 12, 2019·3 cites·3 claims
- 2489US7473557B2Method for targeting transcriptionally active lociREGENERON PHARMA·Filed 2004·Granted Jan 6, 2009·33 cites·8 claims
- 2586US5470952ACNTF and IL-6 antagonistsREGENERON PHARMA·Filed 1993·Granted Nov 28, 1995·47 cites·2 claims
- 2685US11407822B2Treatment of fibrodysplasia ossificans progressivaREGENERON PHARMA·Filed 2019·Granted Aug 9, 2022·2 cites·6 claims
- 2785US10377817B2Human antibodies to GREM1REGENERON PHARMA·Filed 2014·Granted Aug 13, 2019·7 cites·13 claims
- 2885US9677129B2Method for detecting the replacement of an endogenous allele with a modified allele by homologous recombination in a mouse ES cellECONOMIDES ARIS N·Filed 2014·Granted Jun 13, 2017·3 cites·11 claims
- 2985US9382567B2Methods of producing hybrid antibodiesREGENERON PHARMA·Filed 2013·Granted Jul 5, 2016·3 cites·5 claims
- 3084US8414890B2Human antibodies to human RANKL, encoding nucleic acids and methods of treatmentMARTIN JOEL H·Filed 2009·Granted Apr 9, 2013·12 cites·16 claims
- 3182US10584364B2Mice that produce hybrid antibodiesREGENERON PHARMA·Filed 2013·Granted Mar 10, 2020·1 cites·3 claims
- 3282US10531648B2Conditional rodent Acvr1 mutant geneREGENERON PHARMA·Filed 2018·Granted Jan 14, 2020·1 cites·7 claims
- 3382US10470444B2Method for making a genetically modified mouse with an inducible ACVR1 mutation that causes ectopic bone formationREGENERON PHARMA·Filed 2018·Granted Nov 12, 2019·1 cites·21 claims
- 3482US10448621B2Rodent embryonic stem cell with conditional ACVR1 mutant allelesREGENERON PHARMA·Filed 2018·Granted Oct 22, 2019·1 cites·13 claims
- 3581US11419319B2Genetically modified rodent with an inducible ACVR1 mutation in exon 7 that causes ectopic bone formationREGENERON PHARMA·Filed 2019·Granted Aug 23, 2022·2 cites·23 claims
- 3680US10548302B2Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophyREGENERON PHARMA·Filed 2017·Granted Feb 4, 2020·1 cites·30 claims
- 3778US10392633B2Multifunctional allelesREGENERON PHARMA·Filed 2013·Granted Aug 27, 2019·2 cites·12 claims
- 3876US11319557B2Multifunctional allelesREGENERON PHARMA·Filed 2019·Granted May 3, 2022·1 cites·15 claims
- 3975US6075007AModified noggin polypeptide and compositionsREGENERON PHARMA·Filed 1997·Granted Jun 13, 2000·20 cites·6 claims
- 4074US12473574B2Methods for modifying a genomeREGENERON PHARMA·Filed 2022·Granted Nov 18, 2025·0 cites·30 claims
- 4174US2024190974A1Anti-acvr1 antibodies and uses thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 4273US12089576B2Nucleic acids comprising a modified rodent activin a receptor type 1 (Acvr1) geneREGENERON PHARMA·Filed 2022·Granted Sep 17, 2024·0 cites·12 claims
- 4372US7285532B2Therapeutic method for treating bone formation diseasesREGENERON PHARMA·Filed 2003·Granted Oct 23, 2007·2 cites·4 claims
- 4471US2020229406A1Rodents With Conditional ACVR1 Mutant AllelesREGENERON PHARMA·Filed 2019·Application pending·0 cites
- 4570USRE49121EGenetically modified mouse with an inducible ACVR1 gene with a mutant R206H exon 5 that has ectopic bone formationREGENERON PHARMA·Filed 2018·Granted Jul 5, 2022·0 cites·17 claims
- 4670US2023192831A1Human Antibodies to GREM1REGENERON PHARMA·Filed 2023·Application pending·0 cites
- 4768US11730150B2Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophyREGENERON PHARMA·Filed 2019·Granted Aug 22, 2023·0 cites·20 claims
- 4868US6610510B1Morphogenic proteinsREGENERON PHARMA·Filed 1998·Granted Aug 26, 2003·20 cites·8 claims
- 4967US10988776B2Methods of modifying genes in eukaryotic cellsREGENERON PHARMA·Filed 2018·Granted Apr 27, 2021·0 cites·8 claims
- 5067US7576065B2Enhancing neurotrophin-induced neurogenesis by endogenous neural progenitor cells by concurrent overexpression of brain derived neurotrophic factor and an inhibitor of a pro-gliogenic bone morphogenetic proteinCORNELL RES FOUNDATION INC·Filed 2003·Granted Aug 18, 2009·2 cites·26 claims
Showing the top 50 of 72 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Aris N. Economides files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →